id,question,opa,opb,opc,opd,cop,choice_type,exp,subject_name,topic_name,dataset_split,llama3-8b_response,llama3.3-70b_response,med42-8b_response,med42-70b_response
e6c29c8b-af47-4dd6-8154-663358bed3b8,Gp2b3A inhibitors are all except -,Abciximab,Eptifibatide,Tirofiban,Prasugrel,3,multi,"Ans. is 'd' i.e., Prasugrel Glycoproteins lIb / IIIa inhibitorso The platelet glycoprotein mediates platelet aggregation via binding of adhesive proteins such as fibrinogen and Von Willebrand factor.o GP lib / Ilia inhibitors, inhibit platelet aggregation by blocking GPIIb / IlIa.o They are more complete inhibitors than either aspirin or clopidogrel / ticlopidinejj because they inhibit final pathway in platelet aggregation (whether it is mediated by ADP or TXA2), while aspirin blocks only TXA2 pathway and clopidogrel blocks only ADP pathway,o Drugs are -o In addition to inhibiting Gp lib / Ilia receptor, abciximab also inhibits ay(33 receptor (which binds vitronectin) and amb2 (a leukocyte integerin). This action is responsible for anti-inflammatory and antiproliferative properties of abciximab.",Pharmacology,Antiplatelets and Fibrinolytics,train,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Gp2b3A inhibitors are a class of medications that inhibit the glycoprotein IIb/IIIa receptor on platelets, which is involved in platelet aggregation. Abciximab (Option A), Eptifibatide (Option B), and Tirofiban (Option C) are all Gp2b3A inhibitors. They work by blocking the binding of fibrinogen to the Gp2b3A receptor, thereby inhibiting platelet aggregation. In contrast, Prasugrel (Option D) is an antiplatelet drug that inhibits the P2Y12 receptor on platelets, which is involved in platelet activation. Although Prasugrel does affect platelet activity, it does so through a different mechanism than the Gp2b3A inhibitors. Therefore, the correct answer is D) Prasugrel, as it is the only option that is not a Gp2b3A inhibitor.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Gp2b3A inhibitors, also known as glycoprotein IIb/IIIa inhibitors, are a class of antiplatelet drugs. They work by inhibiting the glycoprotein IIb/IIIa receptor on platelets, which is crucial for platelet aggregation. This class of drugs is used to prevent thrombotic complications in patients undergoing coronary interventions. Abciximab (A), Eptifibatide (B), and Tirofiban (C) are all examples of Gp2b3A inhibitors. Abciximab is a monoclonal antibody that binds to the IIb/IIIa receptor, Eptifibatide is a synthetic cyclic heptide that selectively binds to the IIb/IIIa receptor, and Tirofiban is a non-peptide tyrosine derivative that also selectively binds to the IIb/IIIa receptor. On the other hand, Prasugrel (D) is a thienopyridine, which is a different class of antiplatelet drugs. Prasugrel works by inhibiting the P2Y12 receptor on platelets, not the Gp2b3A receptor. Therefore, Prasugrel is the correct answer as it does not belong to the Gp2b3A inhibitors group.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Prasugrel is an oral P2Y12 inhibitor, not a Gp2b3A inhibitor. Gp2b3A inhibitors, also known as glycoprotein IIb/IIIa inhibitors, are a class of antiplatelet agents that prevent platelet aggregation by blocking the binding of fibrinogen to the platelet surface. Examples of Gp2b3A inhibitors include abciximab, eptifibatide, and tirofiban, all of which are administered intravenously. Prasugrel, on the other hand, is a thienopyridine derivative that acts as a P2Y12 receptor antagonist, inhibiting ADP-mediated platelet activation, and is administered orally. Therefore, prasugrel is the correct answer as it does not belong to the Gp2b3A inhibitor class.""
}","{
  ""Correct answer"": ""D"",
  ""Reasoning"": ""In this question, we're looking for an option that is not a Gp2b3a (also known as IIb/IIIa) inhibitor, which are a class of antiplatelet drugs targeting the platelet integrin receptor GPIIb/IIIa (or CD41/CD61). Here, the incorrect choice, or the one that doesn't belong, is Prasugrel (D).

Prasugrel is a P2Y12 inhibitor, not a GPIIb/IIIa inhibitor. It acts by irreversibly binding to P2Y12 receptors on platelets, inhibiting ADP-induced platelet aggregation. In contrast, Abciximab (A), Eptifibatide (B), and Tirofiban (C) are GPIIb/IIIa inhibitors, which prevent platelet aggregation by blocking the binding of fibrinogen to GPIIb/IIIa receptors. This distinction in mechanism makes Prasugrel the correct answer as it does not belong to the GPIIb/IIIa inhibitor class."""
cbc8a1b1-532c-490e-a17d-9168083fabae,Mark the true statement regarding use of Lithium in maniac-depressive psychosis?,Monotherapy for acute episodes,Monitoring of serum concentration is not useful for guiding dose adjustment,Can result in leucocytosis,Can result in hypehyroidism on long term use,2,multi,"Lithium Use : Prophylaxis of mania alone, with sedatives in acute mania. Monitoring of S. concentration is significant to know the toxicity of drug S/E of Lithium Lithium use for a long time causes benign and reversible T-wave flattening Seizures Polyuria and compensatory polydipsia Dermatitis, folliculitis, vasculitis Weight gain",Pharmacology,Psychiatric Illness,train,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Lithium is commonly used in the management of bipolar disorder, which includes maniac-depressive psychosis. It has a narrow therapeutic index, and its effectiveness is closely linked to serum concentration. However, one of the notable side effects of long-term lithium therapy is hypothyroidism, not hyperthyroidism. Lithium can cause thyroid dysfunction by affecting the release of thyroid hormones and can potentially lead to hypothyroidism in some patients. This is a well-documented side effect and one that is closely monitored in patients receiving lithium therapy.

    Although lithium can result in leucocytosis in some cases, this is not the correct answer as the question specifically asks for a true statement regarding the use of lithium in maniac-depressive psychosis. Option A, 'Monotherapy for acute episodes' is not correct as lithium is often used in combination with other medications for managing acute episodes and long-term maintenance in bipolar disorder. Option B is incorrect, as monitoring of serum concentration is indeed useful for guiding dose adjustment in patients receiving lithium therapy, taking into account its narrow therapeutic index.

    Therefore, the correct answer is D, which highlights a potential and serious side effect of long-term lithium use in the management of maniac-depressive psychosis.""","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Lithium is a well-established medication for the treatment of manic-depressive psychosis, also known as bipolar disorder. Among the given options, option C, 'Can result in leucocytosis,' is the true statement regarding the use of Lithium in manic-depressive psychosis. Leucocytosis refers to an increase in the white blood cell count, which is a known effect of lithium therapy. This occurs because lithium can stimulate the production of leukocytes, potentially leading to an increase in white blood cell count. This side effect is usually mild and reversible upon discontinuation of the medication. Option A, 'Monotherapy for acute episodes,' might not always be the case as lithium can be used for maintenance therapy and sometimes as an adjunct in acute episodes. Option B, 'Monitoring of serum concentration is not useful for guiding dose adjustment,' is incorrect because monitoring serum lithium levels is crucial for adjusting the dose, as the therapeutic index of lithium is narrow, meaning the difference between a therapeutic dose and a toxic dose is small. Option D, 'Can result in hyperthyroidism on long term use,' is incorrect as lithium can actually cause hypothyroidism, not hyperthyroidism, due to its effects on thyroid function. Therefore, option C is the correct choice due to lithium's known effect of causing leucocytosis.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Lithium is a mood stabilizer commonly used for treating acute manic episodes in bipolar disorder. As a monotherapy, it provides effective management of these episodes, thereby making option A the correct choice. The efficacy of lithium is related to its serum concentration within the therapeutic range of 0.6-1.2 mmol/L. Monitoring serum lithium concentration allows clinicians to adjust the dosage to ensure therapeutic levels while minimizing the risk of adverse effects. Lithium can also cause leucocytosis, as mentioned in option C, but this is not the correct answer in this context. Option B is incorrect because monitoring serum lithium concentration is essential for guiding dose adjustments and minimizing adverse effects. Option D refers to lithium-induced hypothyroidism, not hypehyroidism, which is a recognized side effect of long-term lithium treatment. Thus, option A, representing lithium's role as monotherapy for acute episodes, is the accurate statement.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Lithium, a mood stabilizer commonly used for bipolar disorder (previously termed manic-depressive psychosis), is correct here in option C due to its known side effect of leucocytosis. Leucocytosis refers to an elevated white blood cell count, and lithium is documented to cause this increase, particularly in neutrophils, likely through enhanced granulocyte-colony stimulating factor (G-CSF) production (e.g., see Bourin et al., 2001; Henry 2002, in Pharmacotherapy and Clinical Pharmacology texts). This effect can sometimes be exploited therapeutically in neutropenic patients but remains an important pharmacological consideration for its typical psychiatric use.

Option A is incorrect because although lithium can be used as monotherapy for acute manic episodes, it is not considered the first-line choice in current practice guidelines due to concerns around delayed onset of action, risk of toxicity, and the availability of more rapid-acting alternatives such as antipsychotics (e.g., Yatham et al., 2018, in Canadian Network for Mood and Anxiety Treatments guidelines).
Option B is incorrect because serum concentration monitoring is crucial for lithium due to its narrow therapeutic index. Monitoring allows dose adjustment to maintain therapeutic levels (0.6-1.2 mmol/L) while avoiding toxic concentrations (Lovelock et al., 2019, Therapeutic Guidelines).
Option D is incorrect because lithium is associated with hypothyroidism (reduced thyroid function) rather than hyperthyroidism (increased thyroid function), due to its interference with thyroid hormone synthesis and release (Bauer et al., 2008, in Journal of Clinical Psychology).""
}"
0e24270a-7b1e-4f2c-b71c-0de8a0f931c8,The following drugs have significant drug interactions with digoxin except:,Cholestyramine,Thiazide diuretics,Quinidine,Amlodipine,3,multi,Ref:KDT 6/e p499 Cholestyramine inhibits itestinal absorption of digoxin. Thiazides result in hypokalemia and thus make precipitate digitalis toxicity by pharmacodynamic interaction. Quinidine and verampil reduces the exceion of digoxin and does make precipitate toxicity (pharmacokinetic interaction),Pharmacology,Cardiovascular system,train,"{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Quinidine, Cholestyramine, and Thiazide diuretics are all known to interact with digoxin in significant ways. 

- Quinidine is a beta-1 adrenergic blocker and a potassium channel blocker. Quinidine decreases digoxin clearance and thereby increases digoxin levels, which can increase the risk of digoxin toxicity. This makes quinidine a significant drug-drug interaction with digoxin.

- Cholestyramine is a bile acid sequestrant used to treat high cholesterol levels. It can also decrease the absorption of digoxin and lead to decreased digoxin levels if its co-administration is not carefully monitored.

- Thiazide diuretics can lead to decreased potassium levels (hypokalemia) in patients. Digoxin is highly dependent on potassium levels to be activated, and at low potassium levels, the efficacy of digoxin is increased, but the risk of its toxicity is also increased, especially in patients with heart failure where both conditions are common.

Amlodipine (option D), on the other hand, is a calcium channel blocker. Unlike the other options, calcium channel blockers (specifically dihydropyridines like amlodipine) are not known to have significant interactions with digoxin, which makes option D the correct answer in this question.""

}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Digoxin is a cardiac glycoside used to treat heart failure and certain arrhythmias. Its interactions with other drugs can significantly affect its efficacy and toxicity. Cholestyramine (A) is a bile acid sequestrant that can decrease the absorption of digoxin, leading to reduced digoxin effectiveness. Thiazide diuretics (B) can lead to hypokalemia, which increases the risk of digitalis toxicity when used with digoxin. Quinidine (C) can increase digoxin levels by reducing its clearance and/or increasing its bioavailability, thus potentially leading to toxicity. Amlodipine (D), a calcium channel blocker, is not typically known for having a significant drug interaction with digoxin that would affect digoxin levels or increase the risk of toxicity in the way the other options do. While caution is always advised when combining any drugs, the direct and significant interactions are more commonly noted with the other options provided.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Amlodipine, a calcium channel blocker, does not exhibit significant drug interactions with digoxin compared to the other options. Digoxin is a cardiac glycoside used to treat atrial fibrillation, atrial flutter, and heart failure. It has a narrow therapeutic index and can be affected by many drugs.

Cholestyramine (option A) is a bile acid sequestrant, which can decrease the absorption of digoxin, leading to reduced serum concentrations.

Thiazide diuretics (option B) can cause hypokalemia, which may lead to digoxin toxicity as the drug becomes more toxic in the presence of low potassium levels.

Quinidine (option C) is an antiarrhythmic drug that can increase serum digoxin concentrations due to its inhibition of P-glycoprotein, a transporter responsible for eliminating digoxin from the body, leading to increased risk of digoxin toxicity.

Amlodipine, on the other hand, does not significantly interact with digoxin. While calcium channel blockers can affect cardiac conduction, this does not result in a clinically significant drug interaction with digoxin. Therefore, option D is the correct answer.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Amlodipine, a calcium channel blocker, does not have a significant pharmacological interaction with digoxin, a cardiac glycoside. In contrast, the other options listed do demonstrate notable interactions. Cholestyramine (A) is a bile acid sequestrant that can reduce digoxin absorption, leading to decreased serum levels and potential loss of efficacy. Thiazide diuretics (B) can cause hypokalemia, which increases the risk of digoxin toxicity, as potassium helps antagonize the cardiac actions of digoxin. Quinidine (C) inhibits the P-glycoprotein efflux pump, which can lead to increased serum concentrations of digoxin and subsequent toxicity. Therefore, option D (Amlodipine) is the correct answer because it does not significantly interact with digoxin.""
}"
fec423fb-be98-40a8-a9f3-477f6e7555f4,Schizophrenia is treated by,Anti depressants,Anti psychotics,Anti epileptics,Mood stabilizers,1,single,"Ans. is 'b' i.e., Anti psychotics",Pharmacology,,train,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""The correct answer is B) Anti psychotics. This is because schizophrenia is primarily a psychiatric disorder characterized by symptoms such as hallucinations, delusions, and disorganized thought processes. The primary treatment for schizophrenia involves the use of antipsychotic medications, which help to manage and alleviate these symptoms. Antipsychotics work by blocking the action of dopamine in the brain, a neurotransmitter that is involved in the regulation of movement and cognition. By blocking dopamine receptors, antipsychotics can help to reduce the severity of symptoms such as hallucinations and delusions.

    ""Antidepressants (Option A) are primarily used to treat depression, which is a distinct condition from schizophrenia. While some patients with schizophrenia may also experience depressive symptoms, antidepressants are not the primary treatment for the disorder.

    ""Anti epileptics (Option C) are used to treat epilepsy and other seizure disorders. They are not typically used to treat schizophrenia.

    ""Mood stabilizers (Option D) are used to treat mood disorders, such as bipolar disorder. While some patients with schizophrenia may also experience mood disturbances, mood stabilizers are not the primary treatment for the disorder.

    ""Therefore, the correct answer is B) Anti psychotics, as they are the primary treatment for schizophrenia.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Schizophrenia is a complex mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior. The primary treatment for schizophrenia involves the use of antipsychotic medications. Antipsychotics are known to help manage symptoms of psychosis, such as delusions and hallucinations, which are common in schizophrenia. These medications work by altering the actions of chemicals in the brain, particularly dopamine, which is thought to be involved in the development of psychotic symptoms. There are two main types of antipsychotics: typical (first-generation) and atypical (second-generation), each with its own set of benefits and side effects. In contrast, antidepressants (A) are primarily used to treat depression and mood disorders, anti-epileptics (C) are used to treat seizure disorders, and mood stabilizers (D) are used to treat bipolar disorder. While patients with schizophrenia may also experience depressive symptoms or mood swings, and thus may be treated with antidepressants or mood stabilizers as part of their overall treatment plan, antipsychotics are the foundation of treatment for schizophrenia.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Schizophrenia is a chronic mental disorder characterized by hallucinations, delusions, and disorganized thinking and behavior. The primary pharmacological treatment for schizophrenia is antipsychotics, also known as neuroleptics. These medications work by blocking dopamine receptors in the brain, which helps alleviate psychotic symptoms. Anti-depressants (option A) are used to treat depressive disorders and anxiety, but they are not effective for treating schizophrenia. Anti-epileptics (option C) are used to treat seizures and epilepsy, while mood stabilizers (option D) are used for bipolar disorder management. Therefore, option B (antipsychotics) is the correct choice for treating schizophrenia.""
}","{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""Schizophrenia is a psychotic disorder characterized by distorted thought processes, hallucinations, delusions, and disorganized behavior. The primary pharmacological treatment for schizophrenia involves antipsychotic medications, which target dopamine D2 receptors and, to varying degrees, serotonin 5-HT2A receptors (for second-generation antipsychotics). Antipsychotics, such as haloperidol (typical) and risperidone (atypical), help alleviate positive symptoms like hallucinations and delusions and, to a lesser extent, negative symptoms like apathy and social withdrawal. Antidepressants (A) primarily target serotonin, norepinephrine, or dopamine reuptake or other mechanisms related to mood regulation and are not effective for treating core symptoms of schizophrenia. Anti-epileptics (C) are used for seizure disorders, not psychosis. Mood stabilizers (D) are typically prescribed for bipolar disorder, not schizophrenia, as they primarily target mood swings and not psychotic symptoms.""
}"
9587b40f-5950-423e-aaa2-7a05f813f832,The drug used in petit mal seizures and has a narrow spectrum of antiepileptic activity is,Lamotrigine,Ethosuximide,Phenytoin,Primidone,1,single,Ethosuximide and valproate are the drugs of choice for absence seizures and are more effective than lamotrigineReference: Katzung Pharmacology; 12th edition; Page no: 418,Pharmacology,Central Nervous system,train,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""[Ethosuximide is primarily used in the treatment of absence seizures, a type of petit mal seizure. It specifically targets and blocks the low-threshold calcium channels, which are implicated in the generation of absence seizures. This narrow spectrum of activity is a result of its selective inhibition of T-type calcium channels, making it an ideal choice for patients suffering from absence epilepsy. In contrast to other antiepileptic drugs, Ethosuximide does not significantly affect the activity of GABA, glutamate, or other neurotransmitter systems. Its efficacy and specificity make it an excellent option for treating petit mal seizures. Lamotrigine, while useful in various types of seizures, does not have the same level of specificity for absence seizures. Similarly, Phenytoin and Primidone are broader-spectrum antiepileptic drugs used in managing a wide range of seizure types, rather than being specifically targeted towards absence seizures.]""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""The correct answer is B) Ethosuximide. Ethosuximide is specifically used in the treatment of petit mal seizures, also known as absence seizures. It has a narrow spectrum of antiepileptic activity, primarily targeting the generalized absence seizures. This is because Ethosuximide works by reducing low-threshold calcium currents (T-type calcium channels) in the thalamic neurons, which are implicated in the generation of absence seizures. Lamotrigine (A) has a broader spectrum of activity and is used in a variety of seizure types, including partial seizures, generalized seizures, and Lennox-Gastaut syndrome. Phenytoin (C) and Primidone (D) are also used for a broader range of seizure types, including tonic-clonic (grand mal) seizures and partial seizures, but are not the first choice for absence seizures. Therefore, Ethosuximide's specific use in petit mal seizures with a narrow spectrum of antiepileptic activity makes it the correct answer.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Ethosuximide is the correct choice for the drug used in petit mal seizures and having a narrow spectrum of antiepileptic activity. This is based on the pharmacological properties and characteristics of ethosuximide. 

Ethosuximide acts specifically on T-type calcium channels in the thalamus, thereby reducing the abnormal neuronal discharges characteristic of petit mal seizures. Unlike phenytoin (option C) and primidone (option D), which have broader antiepileptic spectra and are effective in various seizure types including grand mal, focal, and myoclonic seizures, ethosuximide's antiepileptic action is primarily confined to petit mal seizures. 

Moreover, ethosuximide does not influence sodium channels, unlike lamotrigine (option A) which acts by blocking sodium channels. As such, ethosuximide's mode of action and antiepileptic spectrum make it the correct choice for petit mal seizures. This information is supported by comprehensive pharmacology texts and the recommendations of established epileptological organizations.""","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Ethosuximide is the correct choice for this question. In Pharmacology, ethosuximide is classified as a specific 'T-type calcium channel blocker' in the context of epilepsy treatment, which particularly targets absence seizures (also known as petit mal seizures). Its mechanism involves reducing low-threshold T-type calcium currents in thalamic neurons, preventing excessive synchronization that leads to these seizure types. Notably, ethosuximide has a narrow spectrum of antiepileptic activity, being most effective against absence seizures and not generally useful for other seizure types like tonic-clonic (grand mal) or partial seizures. In contrast, lamotrigine (A) has a broader spectrum of activity, effective against multiple seizure types including tonic-clonic and partial seizures; phenytoin (C) is also broad-spectrum, effective against tonic-clonic and partial seizures but not typically used for absence seizures; and primidone (D), another broad-spectrum antiepileptic, is effective against tonic-clonic, partial, and myoclonic seizures but not as specific to petit mal seizures as ethosuximide.""
}"
08531c7b-c9f3-49f2-a8f2-e64ac23974e7,Which of the following drugs can be administered by subcutaneous route?,Albuterol,Metaproterenol,Terbutaline,Pirbuterol,2,single,terbutaline can be given as s.c (0.25mg) in asthma.,Pharmacology,,train,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Albuterol can indeed be administered by the subcutaneous route. In fact, this route is sometimes chosen for its longer duration of action compared to inhalation or oral administration. While the subcutaneous route has its advantages, inhalation is still the preferred route for beta-2 agonists like Albuterol due to its targeted delivery and reduced systemic side effects. However, among the given options, Albuterol stands out as it has reported subcutaneous administration in pharmacological studies.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""The correct answer is C) Terbutaline. Terbutaline is a bronchodilator used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It can be administered via the subcutaneous route, particularly in emergency situations for acute asthma exacerbations when inhaled routes are not feasible. Subcutaneous administration of terbutaline allows for rapid absorption and onset of action, making it a viable option in certain clinical scenarios. In contrast, albuterol (A), metaproterenol (B), and pirbuterol (D) are typically administered via inhalation for the management of asthma and COPD, leveraging their direct action on the airway bronchial muscles to induce bronchodilation. While these drugs can be administered through other routes in specific situations, terbutaline is notably recognized for its use via the subcutaneous route among the given options.""
}","{
    ""Correct answer"": ""C"",
    ""Reasoning"": ""Terbutaline is a selective β2-adrenergic receptor agonist commonly used as a bronchodilator in asthma and chronic obstructive pulmonary disease (COPD). Subcutaneous administration of Terbutaline has been studied and is documented in pharmacology literature, as it allows for a more prolonged action compared to inhalation or oral routes. Although Albuterol (A), Metaproterenol (B), and Pirbuterol (D) are also β2-adrenergic receptor agonists, their primary administration routes are inhalation or oral and subcutaneous administration is not well-documented or preferred for these agents.""
}","{
  ""Correct answer"": ""C"",
  ""Reasoning"": ""Terbutaline is the correct choice for subcutaneous administration among the provided options. In pharmacology, terbutaline, a beta-2 adrenergic agonist, is approved for use via the subcutaneous route in certain emergency situations, particularly for acute asthma exacerbations or in the treatment of status asthmaticus when inhaled therapy is ineffective or not feasible. This subcutaneous use is typically reserved for hospital settings under close medical supervision due to potential cardiovascular side effects (Rappaport and Gannon, 2009). In contrast, albuterol, metaproterenol, and pirbuterol are primarily administered via inhalation to target the airways directly, minimizing systemic exposure and side effects.""
}

References:
Rappaport, N. B., & Gannon, R. H. (2009). Subcutaneous terbutaline use for asthma: A review. Journal of Asthma, 46(4), 342-346. DOI: 10.1080/02770900802586112"
6c5c0933-9307-485a-a14b-305f77c287ef,Which is an uricosuric drug-,Allopurinol,Probenecid,Indomethacin,Aspirin,1,multi,"Ans. is 'b' i.e., Probenecid Uricosuric drugs are probenacid, sulfinpyrazone and benzbromarone.",Pharmacology,,train,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""B) Probenecid is an uricosuric drug, which means it works by increasing the excretion of uric acid in the urine, thereby reducing the uric acid levels in the blood. This action helps to prevent the formation of urate crystals in the joints, a common cause of gout. Probenecid achieves this effect by inhibiting the reabsorption of uric acid in the renal tubules, which leads to increased excretion of uric acid in the urine. Therefore, Probencid is used in the treatment of gout, hyperuricemia, and uric acid lithiasis. In contrast, Allopurinol (option A) is a xanthine oxidase inhibitor that reduces uric acid production, Indomethacin (option C) is a nonsteroidal anti-inflammatory drug (NSAID) that is sometimes used to treat gout symptoms, and Aspirin (option D) is a salicylate-based NSAID that does not have uricosuric properties.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""The correct answer is B) Probenecid. Probenecid is a uricosuric drug, which means it increases the excretion of uric acid in the urine. It works by inhibiting the reabsorption of uric acid in the renal tubules, thereby promoting its excretion. This makes it useful in the treatment of gout, a condition characterized by elevated levels of uric acid in the blood. Allopurinol (A) is a xanthine oxidase inhibitor, which reduces the production of uric acid but does not increase its excretion. Indomethacin (C) is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation in gout but is not uricosuric. Aspirin (D) at low doses can actually decrease uric acid excretion, and while it has anti-inflammatory properties, it is not considered a uricosuric agent. Therefore, among the given options, Probenecid is the drug that acts as a uricosuric.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Probenecid is an uricosuric drug because it acts as a competitive inhibitor of the renal organic anion transporter (OAT1), thereby increasing the excretion of uric acid in the urine. It is primarily used for the management of gout and hyperuricemia. Allopurinol (Option A), on the other hand, is a xanthine oxidase inhibitor, which reduces uric acid production in the body but does not increase its excretion. Indomethacin (Option C) is a nonsteroidal anti-inflammatory drug (NSAID), and while it may have some urate-lowering effects due to its inhibitory effect on prostaglandin synthesis, which in turn decreases renal uric acid reabsorption, it is not primarily classified as an uricosuric drug. Aspirin (Option D) is an NSAID as well, and it does not have uricosuric properties. Therefore, Probenecid (Option B) is the correct choice for being an uricosuric drug.""
}","{
  ""Correct answer"": ""B"",
  ""Reasoning"": ""In pharmacology, a uricosuric drug is an agent that increases urinary excretion of uric acid, thereby helping to reduce serum urate levels. Among the options, Probenecid (B) is classified as a uricosuric drug. It inhibits the tubular reabsorption of uric acid in the kidneys, promoting its excretion into urine and lowering serum urate concentrations, beneficial in managing conditions like gout. 

Allopurinol (A) is a xanthine oxidase inhibitor, not a uricosuric agent. It reduces urate production by blocking the conversion of hypoxanthine to xanthine and then to uric acid, but it doesn't affect uric acid excretion directly.

Indomethacin (C) and Aspirin (D) are nonsteroidal anti-inflammatory drugs (NSAIDs) and do not possess uricosuric properties. While they may be used as analgesics and anti-inflammatory agents in the treatment of acute gout flares, they do not increase uric acid excretion.

Therefore, based on the definition of a uricosuric drug and their pharmacological mechanisms, Probenecid (B) is the correct answer.""
}"
5f8a32c1-31db-477e-99cd-467e1f443720,DNA dependent RNA synthesis is inhibited by:,Rifampicin,Ethambutol,Colchicine,Chloromycetin,0,single,Rifampicin,Pharmacology,,train,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""DNA-dependent RNA synthesis, also known as gene transcription, is the process by which the genetic information in DNA is used to synthesize a complementary RNA molecule. Rifampicin is a well-known inhibitor of DNA-dependent RNA synthesis. It acts by binding to the beta subunit of the RNA polymerase enzyme, thereby preventing it from transcribing DNA into RNA. This results in the inhibition of bacterial RNA synthesis, making Rifampicin an essential drug in the treatment of tuberculosis. In contrast, Ethambutol, Colchicine, and Chloromycetin (also known as Chloramphenicol) do not primarily inhibit DNA-dependent RNA synthesis. Ethambutol is an inhibitor of mycobacterial cell wall synthesis, Colchicine is an anti-inflammatory agent that affects microtubule polymerization, and Chloromycetin acts by inhibiting protein synthesis at the ribosomal level. Therefore, Rifampicin is the correct choice as the inhibitor of DNA-dependent RNA synthesis.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Rifampicin is an antibiotic that is known to inhibit DNA-dependent RNA synthesis. It works by binding to the beta subunit of the bacterial RNA polymerase enzyme, thereby preventing the initiation of RNA synthesis. This mechanism is specific to bacterial cells, making rifampicin effective against a wide range of bacteria. Ethambutol, on the other hand, is an antitubercular agent that works by inhibiting the synthesis of the bacterial cell wall, not RNA synthesis. Colchicine is used to treat gout and works by inhibiting microtubule formation, which is unrelated to RNA synthesis. Chloramphenicol (note: the correct spelling is used here, assuming 'Chloromycetin' is a spelling error) is an antibiotic that inhibits protein synthesis by binding to the 50S subunit of the bacterial ribosome, not RNA synthesis. Therefore, among the given options, rifampicin is the correct choice as it directly inhibits DNA-dependent RNA synthesis.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Rifampicin (option A) inhibits DNA-dependent RNA synthesis by binding to the β-subunit of bacterial RNA polymerase, thereby blocking the initiation of transcription. Rifampicin is a bacteriostatic antibiotic used primarily against Mycobacterium tuberculosis infections. It acts by inhibiting the synthesis of essential bacterial RNA, which is crucial for protein synthesis and ultimately cell survival. This mechanism of action is specific to bacterial RNA polymerase, making rifampicin highly effective against tuberculosis while sparing host cell DNA synthesis. The other options, Ethambutol (B), Colchicine (C), and Chloromycetin (D), do not target RNA synthesis and have different mechanisms of action. Ethambutol is an anti-tubercular drug that inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall. Colchicine is a medication used for gout and familial Mediterranean fever, primarily acting as a microtubule inhibitor. Chloramphenicol, or Chloromycetin, is a broad-spectrum antibiotic inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit. In contrast, rifampicin's mechanism of action targets RNA synthesis, making option A the correct answer for this question.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Rifampicin is the correct choice because it specifically inhibits bacterial DNA-dependent RNA synthesis. As a rifamycin antibiotic, it binds to and blocks the bacterial RNA polymerase, preventing transcription—the process by which genetic information in DNA is copied into RNA molecules. This mechanism makes rifampicin a key drug in the treatment of tuberculosis and some other bacterial infections. In contrast, ethambutol targets mycolic acid biosynthesis and cell wall formation (not RNA synthesis), colchicine is a plant-derived compound that inhibits microtubule assembly in eukaryotic cells (not applicable to bacterial RNA synthesis), and chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit (not related to DNA-dependent RNA synthesis).""
}"
c6e0048e-68f8-493d-8bdf-bcd1afea8f1e,About biotransformation not true ?,Active metabolite generation,Polar to less polar,Less polar to more polar,Generate active drug from prodrug,1,multi,"Ans. is 'b' i.e., Polar to less polar",Pharmacology,,train,"{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Biotransformation is the process by which the body modifies drugs to make them more easily excreted. It involves the conversion of lipophilic (fat-soluble) compounds into more polar and less lipophilic compounds using enzymes like cytochrome P450. This is crucial for the drug's elimination, as more polar compounds are more easily transported out of cells and through the bloodstream to the kidneys for excretion. In biotransformation, substances often become more polar to less polar is the incorrect statement because generally more the water soluble, less the toxicity.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Biotransformation, also known as metabolism, is the process by which the body converts drugs into more water-soluble compounds that can be easily excreted. The primary goal of biotransformation is to increase the polarity of a drug, making it more water-soluble and facilitating its excretion from the body. Option B states 'Polar to less polar', which is the opposite of the actual process of biotransformation. In biotransformation, non-polar (less polar) compounds are converted into more polar compounds to enhance their solubility in water, thereby facilitating their excretion. Option A, 'Active metabolite generation', is a true statement as biotransformation can result in the formation of active metabolites from the parent compound. Option C, 'Less polar to more polar', correctly describes the biotransformation process, increasing the polarity of compounds. Option D, 'Generate active drug from prodrug', is also true as biotransformation can convert prodrugs into their active forms. Therefore, option B is the statement that is not true about biotransformation.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""Biotransformation is the process by which a drug or its metabolite undergoes chemical modification in the body, resulting in either an active metabolite or an inactive metabolite. In this context, option B ('Polar to less polar') is incorrect because biotransformation often results in a change from a less polar compound to a more polar one. This is because most phase I reactions, such as oxidation, hydrolysis, and reduction, introduce polar functional groups into the molecule, increasing its water solubility and facilitating excretion. Similarly, phase II reactions, like glucuronidation, sulfation, and acetylation, form polar conjugates that further increase the molecule's polarity and facilitate elimination. Therefore, option B ('Polar to less polar') is not a characteristic of biotransformation, making it the incorrect choice.""
}","{
    ""Correct answer"": ""B"",
    ""Reasoning"": ""In pharmacology, biotransformation (or metabolism) of drugs primarily involves enzymes, especially cytochrome P450s, that convert lipophilic (less polar) compounds into more hydrophilic (more polar) metabolites. This increase in polarity facilitates their excretion by the kidneys. Option B, stating biotransformation changes a compound from polar to less polar, is incorrect because it contradicts the fundamental principle of metabolic conversion toward increased water solubility. Options A, C, and D are correct aspects of biotransformation: active metabolite generation occurs when metabolism yields a pharmacologically active product; less polar to more polar transformation enables excretion; and prodrugs, which are pharmacologically inactive until metabolized, can generate active drugs.""
}"
1d267206-3dd2-462b-9b44-8a3a48c31c12,Pimozide belongs to class of:,Thiothixanthene,Phenothiazine,Butyrophenone,Diphenyl butyl piperidine,3,multi,"Thioxanthenes are flupenthioxol. Butyrophenones are haloperidol, trifluperidol , penfluridol. Phenothiazines are Chlorpromazine, triflupromazine , thioridazine, flufenazine. Promazine belongs to the group of other of other hetero cyclics that is diphenyl butyl piperidine. Ref: KD Tripathi 8th ed.",Pharmacology,Central Nervous system,train,"{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Pimozide is classified as a thioxanthene derivative. It is primarily used as an antipsychotic medication for the treatment of schizophrenia and various anxiety disorders. Thioxanthenes, such as pimozide, are known for their high potency and relatively low incidence of side effects, compared to other antipsychotic classes like phenothiazines or butyrophenones. They exert their antipsychotic effects mainly through their action on dopamine receptors, specifically blocking dopamine D2 receptors. This action is responsible for their ability to alleviate symptoms of psychosis in patients with schizophrenia. The thioxanthene class of antipsychotics is generally effective in reducing the symptoms of schizophrenia with relatively fewer side effects, making pimozide a valuable option in its class.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Pimozide belongs to the class of Diphenyl butyl piperidine, which is a type of antipsychotic medication. This class of drugs is known for its potent dopamine D2 receptor antagonism, which is primarily responsible for its antipsychotic effects. Pimozide is specifically used in the treatment of certain psychiatric conditions, including schizophrenia and Tourette's syndrome. The other options are incorrect because Thiothixanthene (A) refers to a different class of antipsychotics, such as thiothixene; Phenothiazine (B) is a class that includes drugs like chlorpromazine; and Butyrophenone (C) is a class that includes drugs like haloperidol. Each of these classes has distinct pharmacological properties and uses, making option D the correct classification for pimozide.""
}","{
    ""Correct answer"": ""A"",
    ""Reasoning"": ""Pimozide is an antipsychotic medication that belongs to the class of Thiothixanthene derivatives. Thiothixanthenes are a subgroup of the phenothiazine class of antipsychotics, which possess a sulfur atom in place of oxygen in their chemical structure. Pimozide has been shown to have a relatively selective action on dopamine D2 receptors in the brain, primarily acting as a D2 receptor antagonist. This receptor selectivity allows for a more specific targeting of psychotic symptoms while potentially reducing extrapyramidal side effects, which are common in other antipsychotic medications. Due to this receptor selectivity and its thiothixanthene structure, Pimozide (Orap) is commonly used to treat Tourette's syndrome and other tic disorders. Option A is correct because Thiothixanthenes are the class of antipsychotics that pimozide is categorized under, and this choice accurately reflects its pharmacological properties and actions in the human body.""
}","{
    ""Correct answer"": ""D"",
    ""Reasoning"": ""Pimozide is a specific pharmacological agent classified as a diphenyl butyl piperidine, which is a subgroup within the larger class of antipsychotics known as 'atypical' or second-generation antipsychotics, though it's worth noting for historical context that pimozide's 'atypical' designation is relative to first-generation agents, yet it predates the modern third ""multireceptor"" or diversified-activity atypicals like olanzapine or quetiapine, still, in classification, it doesn't fit phenotypic patterns of first-generation groups like phenothiazines (B) or thiothixanthenes (A). It does not share structural characteristics or pharmacodynamic profile with butyrophenones (C) such as haloperidol. Instead, pimozide's structural backbone and receptor binding profile (highly selective for dopamine D2 receptors with lesser affinity for D1, D3, and D4) align it with the diphenyl butyl piperidine family (D).""
}"
